Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Q3 net loss widens to $183.2 million; cash totals $960 million

Negative Impact 3 of 5 earnings Written later

Viking Therapeutics reported a third-quarter 2026 net loss of $183.2 million, or $1.55 per share, up from $90.8 million, or $0.81 per share, a year earlier, with no revenue in either period. Research and development expenses rose to $166.8 million from $90.0 million, and the company ended the quarter with $960 million in cash, cash equivalents and short-term investments after September stock and convertible note offerings, which shareholders should weigh against the higher spending.

Key points

  • Q3 2026 net loss of $183.2 million ($1.55 per share) versus $90.8 million ($0.81 per share) in Q3 2025
  • Research and development expenses of $166.8 million, up from $90.0 million; general and administrative expenses of $20.3 million, up from $8.6 million
  • Cash, cash equivalents and short-term investments of $960 million at September 30, 2026, versus $706 million at December 31, 2025
  • Positive top-line maintenance study results for VK2735 announced in the quarter; VANQUISH Phase 3 trials expected to complete in 2027

The filing

CompanyViking Therapeutics, Inc. (VKTX)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:10 PM ET
Accession number0001193125-26-436145

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.